Treatment intensification and risk factor control toward more clinically relevant quality measures

Medical Care

Volumn 47, Issue 4, 2009, Pages 395-402

  Selby, Joseph V ^a   Uratsu, Connie S ^a   Fireman, Bruce ^a   Schmittdiel, Julie A ^a   Peng, Tiffany ^a   Rodondi, Nicolas ^b   Karter, Andrew J ^a   Kerr, Eve A ^c  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Medical School   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Hyperlipidemia; Hypertension; Quality of health care

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRESCRIPTION; QUALITY CONTROL; RISK FACTOR; RISK MANAGEMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; UNITED STATES; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DRUG THERAPY; HEALTH CARE QUALITY; HEALTH INSURANCE; METHODOLOGY; MIDDLE AGED; STANDARD; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CALIFORNIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS; DRUG THERAPY; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY INDICATORS, HEALTH CARE; RISK FACTORS;

EID: 64249157372     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31818d775c     Document Type: Article

References (54)

1. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Cirulation. 1991;83:356-362.
2. Poulter N. Coronary heart disease is a multi-factorial disease. Am J Hypertens. 1999;12(10 Pt 2):92S-95S.
3. Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol. 1998;27:636-641.
4. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003; 290:891-897.
5. Khot UB, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel HI). JAMA. 2001;285:2486-2497.
8. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 2003;26(Suppl 1):S25-S27.
9. Snow V, Aronson MD, Hornbake ER, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-649.
10. Snow V, Weiss KB, Mottur-Pilson C. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med. 2003;138:587-592.
11. Borzecki AM, Wong AT, Hickey EC, et al. Hypertension control: how well are we doing? Arch Intern Med. 2003;163:2705-2711.
12. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465-474.
13. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98:204-208.
14. Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 2003;138:81-89.
15. Berlowitz DR, Ash AS, Glickman M, et al. Developing a quality measure for clinical inertia in diabetes care. Health Serv Res. 2005;40:1836-1853.
16. Asch SM, McGlynn EA, Hiatt L, et al. Quality of care for hypertension in the United States. BMC Cardiovasc Disord. 2005;5:1.
17. Shrank WH, Asch SM, Adams J, et al. The quality of pharmacologic care for adults in the United States. Med Care. 2006;44:936-945.
18. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
19. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens (Greenwich). 2000;2: 324-330.
20. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588-594.
21. Rose AJ, Berlowitz DR, Orner MB, et al. Understanding uncontrolled hypertension: is it the patient or the provider? J Clin Hypertens (Greenwich). 2007;9:937-943.
22. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825-834.
23. Asai Y, Heller R, Kajii E. Hypertension control and medication increase in primary care. J Hum Hypertens. 2002;16:313-318.
24. Kerr EA, Krein SL, Vijan S, et al. Avoiding pitfalls in chronic disease quality measurement: a case for the next generation of technical quality measures. Am J Manag Care. 2001;7:1033-1043.
25. Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care. 2003;41:1173-1182.
26. Voorham J, Denig P, Wolffenbuttel BH, et al. Cross-sectional versus sequential quality indicators of risk factor management in patients with type 2 diabetes. Med Care. 2008;46:133-141.
27. Pogach L, Engelgau M, Aron D. Measuring progress toward achieving hemoglobin ale goals in diabetes care: pass/fail or partial credit. JAMA. 2007;297:520-523.
28. Hayward R. All-or-nothing treatment targets make bad performance measures. Am J Manag Care. 2007;13:126-128.
29. Rodondi N, Peng T, Karter AJ, et al. Treatment intensifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144:475-484.
30. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10(2 Pt 2): 163-170.
31. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;182:703-710.
32. Ash A, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev. 2000;21:7-28.
33. DxCG web site. Available at: http://wwvv.dxcg.com/solunons/global.asp.
34. Alexander MA, Tekawa I, Hunkeler E, et al. Evaluating hypertension control in a managed care setting. Arch Intern Med. 1999; 159:2673-2677.
35. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin Ale in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004;50:166-174.
36. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J. 2002;23:528-535.
37. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577-581.
38. Kirk JK, D'Agostino RB Jr, Bell RA, et al. Disparities in HbAlc levels between African-American and Non-Hispanic white adults with diabetes: a meta-analysis. Ann Pharmacother. 2005;39:1489-1501.
39. Bosworth HB, Dudley T, Olsen MK, et al. Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006;119: 70.e9-el5.
40. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777-784.
41. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
42. Kerr EA, Zikmund-Fisher BJ, Klamerus ML, et al. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med. 2008;148:717-727.
43. Morgenstern H. Ecologic studies in epidemiology: concepts, principles, and methods. Annu Rev Public Health. 1995;16:61-81.
44. Johnston SC. Combining ecological and individual variables to reduce confounding by indication: case study-subarachnoid hemorrhage treatment. J Clin Epidemiol. 2000;53:1236-1241.
45. Johnston SC, Henneman T, McCulloch CE, et al. Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol. 2002;156:753-760.
46. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 2008;168:271-276.
47. Mangione CM, Gerzoff RB, Williamson DF, et al. Association of Diabetes Disease Management Programs' intensity with process and outcomes measures of quality of care: the Translating Research into Action for Diabetes (TRIAD) Study. Ann Intern Med. 2006;145:107-116.
48. Landon BE, Hicks LS, O'Malley AJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med. 2007; 356:921-934.
49. Duru OK, Mangione CM, Steers NW, et al. The association between clinical care strategies and the attenuation of racial/ethnic disparities in diabetes care: the Translating Research into Action for Diabetes (TRIAD) Study. Med Care. 2006;44:1121-1128.
50. Ackermann RT, Thompson TJ, Selby JV, et al. Is the number of documented diabetes process-of-care indicators associated with cardiometabolic risk factor levels, patient satisfaction, or self-rated quality of diabetes care? Diabetes Care. 2006;29:2108-2113.
51. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70.
52. Heisler M, Hogan MM, Hofer TP, et al. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008;117:2884-2892.
53. Pogach LM, Tiwari A, Maney M, et al. Should mitigating comorbidities be considered in assessing healthcare plan performance in achieving optimal glycemic control? Am J Manag Care. 2007;13:133-140.
54. Karter AJ, Parker MM, Moffet HH, et al. Poor medication adherence for newly prescribed cardiometabolic therapies in diabetes: an under-recognized public health issue. Am J Manag Care. 2008. In press.